Bob Ulrich

Bio

Dr. Bob Ulrich is a Managing Director investing in the Life Sciences sector at Vanguard. Bob is a seasoned veteran of both the health care industry and venture capital community, earning prominence as a technologist, operating executive, CEO, entrepreneur and venture capital investor. Prior to joining Vanguard Ventures, Bob was co-founder and President of VanMed, a Vanguard sponsored business incubator specialized in seed stage medical opportunities. He played an active role in several VanMed companies, serving as CEO of five and a Board of Directors member of seven. Bob was President and CEO of Menlo Care, Inc., a spinout of Raychem, which was later acquired by Johnson & Johnson. He served as President and CEO of MedVest, Inc., a medical incubator, responsible for analyzing the business and technology aspects of products for investment and acquisition. Bob's career in the medical industry began at General Electric and continued at Johnson & Johnson where he was Director of New Technologies. In this capacity he directed U.S. and international medical products business development, investments and acquisitions for therapeutic and diagnostic devices and pharmaceuticals. His most notable acquisition was that of the Schatz-Palmaz coronary stent, which has become one of the most successful medical devices in history. He earned his Bachelor of Arts degree in Physics from Claremont McKenna College, and a Master of Science degree and Ph.D. in Polymer Science and Engineering from the University of Massachusetts.